A detailed history of Exane Derivatives transactions in Kiniksa Pharmaceuticals, Ltd. stock. As of the latest transaction made, Exane Derivatives holds 9,496 shares of KNSA stock, worth $189,350. This represents 0.06% of its overall portfolio holdings.

Number of Shares
9,496
Previous 9,496 -0.0%
Holding current value
$189,350
Previous $94,000 2.13%
% of portfolio
0.06%
Previous 0.03%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Apr 22, 2022

SELL
$9.3 - $12.37 $7,542 - $10,032
-811 Reduced 7.87%
9,496 $94,000
Q4 2021

Jan 28, 2022

SELL
$10.39 - $15.15 $4,841 - $7,059
-466 Reduced 4.33%
10,307 $121,000
Q3 2021

Oct 26, 2021

BUY
$11.39 - $16.23 $14,442 - $20,579
1,268 Added 13.34%
10,773 $122,000
Q2 2021

Jul 28, 2021

BUY
$13.22 - $19.09 $38,880 - $56,143
2,941 Added 44.8%
9,505 $132,000
Q1 2021

Apr 30, 2021

SELL
$16.68 - $23.97 $21,667 - $31,137
-1,299 Reduced 16.52%
6,564 $121,000
Q4 2020

Jan 27, 2021

BUY
$14.8 - $21.15 $38,184 - $54,566
2,580 Added 48.84%
7,863 $138,000
Q3 2020

Oct 06, 2020

BUY
$15.21 - $25.53 $15,711 - $26,372
1,033 Added 24.31%
5,283 $80,000
Q2 2020

Jul 10, 2020

SELL
$15.08 - $26.0 $24,731 - $42,640
-1,640 Reduced 27.84%
4,250 $108,000
Q1 2020

Apr 17, 2020

BUY
$11.0 - $19.76 $64,790 - $116,386
5,890 New
5,890 $91,000

Others Institutions Holding KNSA

About Kiniksa Pharmaceuticals, Ltd.


  • Ticker KNSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,470,400
  • Market Cap $687M
  • Description
  • Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...
More about KNSA
Track This Portfolio

Track Exane Derivatives Portfolio

Follow Exane Derivatives and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

News

Stay updated on Exane Derivatives with notifications on news.